BIRCWH - Scholar, Angela D. M. Kashuba

TABLE OF CONTENTS:

RESEARCH INTERESTS:

My research interests involve (1) using phenotyping/genotyping techniques to elucidate the genetic and environmental influences leading to sex differences in drug metabolizing enzyme activity and variability in HIV-1 infection (resulting in differences in antiretroviral efficacy and toxicity) to design maximally effective and minimally toxic antiretroviral regimens, and (2) to characterize drug concentrations in female and male genital secretions (a possible determinant of the sexual transmission of HIV-1, and a possible reservoir for drug resistant HIV-1) to provide a rational basis for future antiretroviral therapies. Although primarily pharmacologic in nature, a multidisciplinary approach is critical for these projects. The collaboration of pharmacology (PharmD), clinical (MD) and basic science (PhD); genetics, virology) researchers allows for comprehensive investigation of mechanisms underlying these clinical challengers, and will result in the development of optimal interventions.

BIRCWH MENTOR:

Myron S. Cohen, MD
Professor
UNC, Department of Medicine
547 Burnett-Womack Bldg., CB#7030
Chapel Hill, NC
(919) 966-2536

EDUCATION:

Bachelor of Science:	University of Toronto Toronto, Ontario, Canada Pharmacy	1986-1990
Residency:	Women's College Hospital Toronto, Ontario, Canada General Practice Pharmacy Residency	1990-1991
Specialist:	Mount Sinai Hospital Toronto, Ontario, Canada Critical Care Clinical Pharmacy	1991-1993
Doctor of Pharmacy:	State University of New York at Buffalo Amherst, NY	1993-1995
Fellowship:	Clinical Pharmacology Research Center Bassett Healthcare Coopertown, NY	1995
Board Certification:	American Board of Clinical Pharmacology

PROFESSIONAL ORGANIZATIONS:

American Society for Clinical Pharmacology and Therapeutics

American Society for Microbiology

Society of Infectious Diseases Pharmacists

The Alliance for the Prudent Use of Antibiotics

The American Association of Colleges of Pharmacy

The American College of Clinical Pharmacy

The American Society of Health-System Pharmacists

Rho Chi Pharmaceutical Honor Society

The Ontario College of Pharmacists

CURRENT PUBLICATIONS:

Last Updated: 10/07/02
Becker S, Fisher A, Flexner C, Gerber JG, Haubrich JJ, Naderer OJ, Pereira AS, Fiscus SA, Wire MB, and Kashuba ADM. "Effects of Formulation and Dosing Strategy on Amprenavir (APV) Concentrations in the Seminal Plasma (SP) of HIV-1 Infected Males. In review. Antimicrobial Agents and Chemotherapy, (2001). Chaudry NI, Eron JJ, Naderer OJ, Pereira AS, Fiscus SA, Wire MB, and Kashuba ADM. "Effects of Formulation and Dosing Strategy on Amprenavir (APV) Concentrations in the Seminal Plasma (SP) of HIV-1 Infected Males. In review. Antimicrobial Agents and Chemotherapy, (2001). Hosseinipour M, Cohen MS, Vernazza PL and Kashuba ADM. "Effects on Antiretroviral Therapy on the Sexual Transmission of HIV-1." In review, Clinical Infectious Diseases, (2001). Jordan HL, Pereira AS, Cohen MS, and Kashuba ADM. "Domestic Cats as Models for Predicting Human Nucleoside Analogue Pharmacokinetics in Blood and Seminal Plasma." Antimicrobial Agents and Chemotherapy, 45:2173-2176 (2001). Vernazza PL, Kashuba ADM, and Cohen MS. "Biological correlates of sexual transmission of HIV: Practical consequences and potential targets for public health." Reviews in Medical Microbiology, 12:131-142 (2001). Streetman DS, Kashuba ADM, Bertino JS, Kulawy R, Rocci ML, and Nafziger AN. "Use of Midazolam urinary Metabolic Ratios for Cytochrome P4503A (CYP3A) Phenotyping." Pharmacogenetics, 11(4):349-355 (2001). Nafziger AN, Bertino JS, Goss-Bley AI, and Kashuba ADM. "Sexual dysfunction and fluvoxamine therapy." Journal of Clinical Psychiatry, 62(2):127-128 (2001). Ozdemir V, Kalow W, Tang B-K, Paterson AD, Walker SE, Endrenyi L and Kashuba ADM. "Evaluation of the genetic component of variability in CYP3A4 activity: a repeat drug administration (RDA) method." Pharmacogenetics, in press (2000). Ozdemir V, Kalow W, Tang B-K, Paterson AD, Walker SE, Endrenyi L, and Kashuba ADM. "Evaluation of the genetic component of variability in CYP3A4 activity: a repeat drug administration (RDA) method." Pharmacogentics, 10(5):373-388 (2000). Pereira AS, Kashuba ADM, Fiscus SA, Hall JE, Tidwell RR, Troiani L, Dunn JA, Eron JJ Jr. and Cohen MS. "Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and viral burden." Journal of Infectious Diseases, 180:2039-43 (1999). Kashuba ADM, Dyer J, Eron JJ, Kramer LM, Raasch RH and Cohen MS. "Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1." Antimicrob Agents Chemother, 43:1817-26 (1999). Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML, Kulawy RW, Beck DJ and Bertino JS Jr. "Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity." Pharmacogenetics, 9:453-62 (1999). Kashuba ADM, Nafziger AN, Drusano GL and Bertino Jr. JS. "Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria." Antimicrob Agents Chemother, 43:623-629 (1999). Nafziger AN, Bertino JS Jr., Goss-Bley A and Kashuba ADM. "Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy." J Clin Psych, 60:187-90 (1999). Kashuba ADM, Bertino JS, Rocci ML et al. "Quantification of intraindividual variability, and the influence of sex and menstrual cycle phase, on CYP3A as measured by phenotyping with intravenous midaxolam." Clin Pharmacol Ther, 64:269-77 (1998). Kashuba ADM, Nafziger AN, Kearns GL et al. "Quantification of intraindividual variability, and the influence of sex and menstrual cycle phase, on CYP2D6 as measured by dextromethorphan phenotyping." Pharmacogentics, 8:403-10 (1998). Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML, Kulawy RW, Beck DJ, Bertino JS Jr. "Effect of fluvoxamine on the activities of CYP1A2, CYP2D6, and CYP3A, as determined by phenotyping." Clin Pharmacol Ther, 64:257-68 (1998). Kashuba ADM, Bertino JS Jr. and Nafziger AN. "Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response using individualized pharmacokinetic monitoring in gram-negative pneumonia." Antimicrobial Agents and Chemotherapy, 42(7):1842-45 (1998). Kashuba ADM, Bertino JS, Kearns GL, et al. "Quantification of long-term intraindividual variability, and the influence of sex and menstrual cycle phase, on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activities as determined by caffeine phenotyping." Clin Pharmacol Ther, 63:540-51 (1998). Trepanier EF, Nafziger AN, Kearns GL, Kashuba ADM and Amsden GW. "Absence of effect of terbinafine on the activity of CYP1A2, NAT-2, and xanthine oxidase. J Clin Pharmacol, 28:424-28 (1998). Kashuba ADM and Nafziger AN. "Physilogical changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs." Clinical Pharmacokinetics, 34(3):203-18 (1998). Kashuba ADM and Amsden G. "Bronchopulmonary Pharmacokinetics of Claithromycin and Azithromycin." Antimicrobial Agents and Chemotherapy, 42(2):481-82 (1998). Kashuba ADM, Ballow C and Forrest A. "Development of a Population Pharmacokinetic Model and Optimal Sampling Strategies for Intravenous Ceftazidime in the Critically III." Antimicrobial Agents and Chemotherapy, 40(8):1860-65 (1996). Kashuba ADM and Ballow C. "Legionella Urinary Antigen Testing: Potential Impact on Diagnosis and Anitbiotic Therapy." Diagnostic Microbiology and Infectious Disease, 24(4):129-39 (1996). Kashuba ADM, Gee S, Lane G and Moy D. "Inflammatory Bowel Disease: Advances in Therapy, On Continuing Practice." 19(4):21-26 (1992).